CEO Tried AI in Drug Testing–Here's Why It Failed
Failed to add items
Sorry, we are unable to add the item because your shopping basket is already at capacity.
Add to cart failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
CEO Tried AI in Drug Testing–Here's Why It Failed
-
Narrated by:
-
Written by:
About this listen
In today’s episode, Dinkar Sindhu, CEO of Axis Clinicals, dives into the world of clinical research and the cautious integration of AI in drug development.
From testing groundbreaking GLP-1 drugs like Ozempic to navigating the complexities of FDA approvals, Dinkar reveals the meticulous process behind ensuring that new drugs are safe and effective.
“AI can help, but it must be traceable and reproducible,” he explains, sharing lessons from a pilot program where inconsistent AI outputs raised red flags.
Join us for an insightful look at how clinical trials shape the future of medicine, the challenges of AI in ensuring data integrity, and why human oversight remains vital.
No reviews yet